Microdosing GLP-1 Receptor Agonists During Perimenopause: A Clinical Approach to Hormonal Weight Gain Written and edited by Sarah Bonza MD, MPH, FAAFP, MSCP, DipABLM, NBC-HWC Perimenopause represents a challenging time for women, with up to 70% experiencing weight gain due to declining estrogen levels, decreased energy expenditure, and metabolic changes
Contact NHS 111 for urgent non-emergency advice
Sweet, Ph.D
Testosterone is central to male fertility, but levels have been declining
Every patient who walks through our door receives a personalized plan, and our providers are GLP-1 certified specifically to ensure safe, effective outcomes from day one
1,2,3 These prescription drugs serve to release the hormone (GLP-1) that in turn releases insulin, which helps balance metabolic processes as well as glucose